Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK

Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1764-71. doi: 10.1161/ATVBAHA.109.192609. Epub 2009 Sep 3.

Abstract

Objective: Abdominal aortic aneurysm (AAA) is a life-threatening disease affecting almost 10% of the population over age 65. Generation of AAAs by infusion of angiotensin (Ang) II in apolipoprotein E-knockout (ApoE(-/-)) mice is an animal model which supports an imbalance of the renin-angiotensin system in the pathogenesis of AAA. The effect of statins on AngII-mediated AAA formation and the associated neovascularization is not known. Here we determined the effect of simvastatin and the ERK inhibitor, CI1040, on AngII-stimulated AAA formation.

Methods and results: ApoE(-/-) mice infused for 28 days with AngII using osmotic minipumps were treated with placebo, 10 mg/kg/d simvastatin, or 100 mg/kg/d CI1040. 95% of AngII-treated mice developed AAA with neovascularization of the lesion, increased ERK phosphorylation, MCP-1 secretion, and MMP activity. These effects were markedly reversed by simvastatin and in part by CI1040. Furthermore, simvastatin and the ERK inhibitor U0126 reversed AngII-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells.

Conclusions: These data support the conclusion that simvastatin interferes with AAA formation induced by AngII in ApoE(-/-) mice at least in part via ERK inhibition.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin II
  • Animals
  • Aortic Aneurysm, Abdominal / chemically induced
  • Aortic Aneurysm, Abdominal / metabolism
  • Aortic Aneurysm, Abdominal / pathology
  • Aortic Aneurysm, Abdominal / prevention & control*
  • Apolipoproteins E / metabolism
  • Apolipoproteins E / pharmacology
  • Benzamides / pharmacology
  • Blood Pressure / drug effects
  • Blotting, Western
  • Disease Models, Animal
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Immunohistochemistry
  • MAP Kinase Kinase Kinase 3 / antagonists & inhibitors*
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Random Allocation
  • Reference Values
  • Renin-Angiotensin System / drug effects
  • Simvastatin / pharmacology*

Substances

  • 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide
  • Apolipoproteins E
  • Benzamides
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Angiotensin II
  • Simvastatin
  • MAP Kinase Kinase Kinase 3
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9